Identification

Name
Arotinolol
Accession Number
DB09204
Type
Small Molecule
Groups
Investigational
Description

Arotinolol is an alpha- and beta-receptor blocker developed in Japan. It is a thiopropanolamine with a tertiary butyl moiety. It has been studied for its potential to be an antihypertensive therapy.[6] Artinolol is being developed by Sumitomo Pharmaceutical Co., Ltd. and it is currently under clinical trials.[10]

Structure
Thumb
Synonyms
Not Available
External IDs
S-596
International/Other Brands
Almarl
Categories
UNII
394E3P3B99
CAS number
68377-92-4
Weight
Average: 371.53
Monoisotopic: 371.07959045
Chemical Formula
C15H21N3O2S3
InChI Key
BHIAIPWSVYSKJS-UHFFFAOYSA-N
InChI
InChI=1S/C15H21N3O2S3/c1-15(2,3)17-6-9(19)7-21-14-18-10(8-22-14)11-4-5-12(23-11)13(16)20/h4-5,8-9,17,19H,6-7H2,1-3H3,(H2,16,20)
IUPAC Name
5-(2-{[3-(tert-butylamino)-2-hydroxypropyl]sulfanyl}-1,3-thiazol-4-yl)thiophene-2-carboxamide
SMILES
CC(C)(C)NCC(O)CSC1=NC(=CS1)C1=CC=C(S1)C(N)=O

Pharmacology

Indication

Artinolol was introduced to be used as an antihypertensive agent since 1986.[7] It has been studied for other functions like tremor control for patients with Parkinson disease and it is currently in clinical trials for its use in the control of blood pressure and heart rate.[10]

Pharmacodynamics

Preclinical studies showed a lack of intrinsic sympathomimetic activities or membrane-establishing properties. It is confirmed that arotinolol presents vasorelaxant activity. This characteristic is also proved to be mainly mediated by its α1-blocking property. In preclinical hypertension trials, there is a specific acute bradycardiac and antihypertensive activity with a pronounced reduction in heart rate. Some reports indicate a delayed development of hypertension when arotinolol is administered daily. Arotinolol has a dose-dependent decrease in cardiac contractility and coronary blood flow as well as an increase in total peripheral resistance. The effects of arotinolol have been confirmed in clinical trials where this drug was able to decrease cardiac index and thus, blood pressure.[6]

Mechanism of action

Arotinolol binds to the β1-, β2- and α1- adrenergic receptor sites with a very high affinity. Radioligand studies have shown that arotinolol presents a higher affinity to the β-receptor compared to the α-receptor. The elucidated mechanism of action seems to be the result of a reduction in the cardiac output via the β-blockade and an additional inhibition of the counter-regulatory increase in peripheral resistance mediated by the α-blockade.[6]

TargetActionsOrganism
ABeta-1 adrenergic receptor
antagonist
Human
ABeta-2 adrenergic receptor
antagonist
Human
AAlpha-1 adrenergic receptors
antagonist
Human
Absorption

Arotinolol gets rapidly absorbed and distributed in the plasma. The plasma concentration peaks 2 hours after initial administration.[5]

Volume of distribution

The stereospecificity of arotinolol is very important for its pharmacokinetic characteristics. The S-enantiomer is highly retained in red blood cells. The distribution studies have shown that arotinolol is mainly distributed from the plasma to the liver followed by the lungs and lastly in the heart. The distribution in the liver was independent on the stereochemistry of the molecules.[8]

Protein binding

The stereospecificity of arotinolol is very important for its pharmacokinetic characteristics. Arotinolol is highly bound to serum proteins reaching a ratio of the original dose of 95.3% in the form of the R-enantiomer and 84.5% of the S-enantiomer. The presented stereospecificity is thought to be related to the α1-acid glycoprotein.[8]

Metabolism

The stereospecificity of arotinolol is very important for its pharmacokinetic characteristics. The R-enantiomer remains unchanged and it is eliminated from the organism by urine in this form while the S-enantiomer is metabolized.[6]

Route of elimination

The stereospecificity of arotinolol is very important for its pharmacokinetic characteristics. Both of the enantiomers were found in urine, suggesting this as the major elimination pathway. It is possible to find arotinolol in urine 2-4 hours after initial administration.[6]

Half life

The reported half-life of arotinolol is 7.2 hours.[6]

Clearance
Not Available
Toxicity

The major toxic effects reported for arotinolol-like drugs are the presence of central nervous system depression.[9]

Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limonene(4R)-limonene may decrease the antihypertensive activities of Arotinolol.Investigational
1,10-Phenanthroline1,10-Phenanthroline may increase the bradycardic activities of Arotinolol.Experimental
4-Methoxyamphetamine4-Methoxyamphetamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Experimental, Illicit
AcebutololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Acebutolol.Approved, Investigational
AceclofenacAceclofenac may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AcemetacinAcemetacin may decrease the antihypertensive activities of Arotinolol.Approved, Experimental, Investigational
AcepromazineArotinolol may increase the orthostatic hypotensive activities of Acepromazine.Approved, Vet Approved
AceprometazineAceprometazine may increase the hypotensive activities of Arotinolol.Approved
AcetohexamideArotinolol may increase the hypoglycemic activities of Acetohexamide.Approved, Investigational, Withdrawn
AcetylcholineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Acetylcholine.Approved
AcetyldigitoxinArotinolol may increase the bradycardic activities of Acetyldigitoxin.Approved
AcetyldigoxinArotinolol may increase the bradycardic activities of Acetyldigoxin.Experimental
Acetylsalicylic acidAcetylsalicylic acid may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
AdapaleneAdapalene may decrease the antihypertensive activities of Arotinolol.Approved
AgmatineThe risk or severity of hypotension can be increased when Arotinolol is combined with Agmatine.Experimental, Investigational
AlaproclateThe serum concentration of Arotinolol can be increased when it is combined with Alaproclate.Experimental
AlclofenacAlclofenac may decrease the antihypertensive activities of Arotinolol.Approved, Withdrawn
AldesleukinThe risk or severity of adverse effects can be increased when Arotinolol is combined with Aldesleukin.Approved
AlfentanilAlfentanil may increase the bradycardic activities of Arotinolol.Approved, Illicit
AlfuzosinArotinolol may increase the orthostatic hypotensive activities of Alfuzosin.Approved, Investigational
AlimemazineAlimemazine may increase the hypotensive activities of Arotinolol.Approved, Vet Approved
AliskirenThe risk or severity of adverse effects can be increased when Arotinolol is combined with Aliskiren.Approved, Investigational
AlminoprofenAlminoprofen may decrease the antihypertensive activities of Arotinolol.Experimental
AmbenoniumAmbenonium may increase the bradycardic activities of Arotinolol.Approved
AmifostineThe risk or severity of adverse effects can be increased when Amifostine is combined with Arotinolol.Approved, Investigational
AmilorideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Amiloride.Approved
AmiodaroneThe therapeutic efficacy of Arotinolol can be increased when used in combination with Amiodarone.Approved, Investigational
AmitrazAmitraz may increase the atrioventricular blocking (AV block) activities of Arotinolol.Vet Approved
AmitriptylineArotinolol may increase the orthostatic hypotensive activities of Amitriptyline.Approved
AmlodipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Amlodipine.Approved
AmobarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Amobarbital.Approved, Illicit
AmodiaquineThe metabolism of Arotinolol can be decreased when combined with Amodiaquine.Approved, Investigational
AmoxapineArotinolol may increase the orthostatic hypotensive activities of Amoxapine.Approved
Amphotericin BThe risk or severity of adverse effects can be increased when Amphotericin B is combined with Arotinolol.Approved, Investigational
AmrinoneThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Amrinone.Approved
Amyl NitriteThe risk or severity of adverse effects can be increased when Arotinolol is combined with Amyl Nitrite.Approved
AndrographolideAndrographolide may decrease the antihypertensive activities of Arotinolol.Investigational
AnisodamineAnisodamine may decrease the antihypertensive activities of Arotinolol.Investigational
AntipyrineAntipyrine may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
ApocyninApocynin may decrease the antihypertensive activities of Arotinolol.Investigational
ApomorphineApomorphine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
ApraclonidineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Apraclonidine.Approved
ApremilastApremilast may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
AranidipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Aranidipine.Approved, Investigational
ArecolineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Arecoline.Experimental
AripiprazoleAripiprazole may increase the hypotensive activities of Arotinolol.Approved, Investigational
Arsenic trioxideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Arsenic trioxide.Approved, Investigational
AsenapineArotinolol may increase the orthostatic hypotensive activities of Asenapine.Approved
AtenololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Atenolol.Approved
AzapropazoneAzapropazone may decrease the antihypertensive activities of Arotinolol.Withdrawn
AzelastineAzelastine may decrease the antihypertensive activities of Arotinolol.Approved
AzelnidipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Azelnidipine.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Azilsartan medoxomil.Approved, Investigational
AzimilideThe risk or severity of hypotension, conduction block, and bradycardia can be increased when Arotinolol is combined with Azimilide.Investigational
BalsalazideBalsalazide may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
BarbexacloneBarbexaclone may increase the hypotensive activities of Arotinolol.Experimental
BarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Barbital.Illicit
BarnidipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Barnidipine.Approved
BenazeprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Benazepril.Approved, Investigational
BencyclaneThe risk or severity of hypotension can be increased when Arotinolol is combined with Bencyclane.Experimental
BendazacBendazac may decrease the antihypertensive activities of Arotinolol.Experimental
BendroflumethiazideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bendroflumethiazide.Approved
BenidipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Benidipine.Approved, Investigational
BenorilateBenorilate may decrease the antihypertensive activities of Arotinolol.Experimental
BenoxaprofenBenoxaprofen may decrease the antihypertensive activities of Arotinolol.Withdrawn
BenzphetamineThe therapeutic efficacy of Benzphetamine can be decreased when used in combination with Arotinolol.Approved, Illicit
BenzydamineBenzydamine may decrease the antihypertensive activities of Arotinolol.Approved
BepridilThe risk or severity of hypotension can be increased when Arotinolol is combined with Bepridil.Approved, Withdrawn
BetaxololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Betaxolol.Approved, Investigational
BethanecholThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bethanechol.Approved
BethanidineBethanidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
BevantololArotinolol may increase the orthostatic hypotensive activities of Bevantolol.Approved
BevoniumBevonium may decrease the antihypertensive activities of Arotinolol.Experimental
BioallethrinThe risk or severity of hypotension can be increased when Arotinolol is combined with Bioallethrin.Approved, Experimental
BisoprololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bisoprolol.Approved
BL-1020BL-1020 may increase the hypotensive activities of Arotinolol.Investigational
BortezomibThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bortezomib.Approved, Investigational
BretyliumThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bretylium.Approved
BrexpiprazoleArotinolol may increase the orthostatic hypotensive activities of Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
BromfenacBromfenac may decrease the antihypertensive activities of Arotinolol.Approved
BromocriptineBromocriptine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
BucillamineBucillamine may decrease the antihypertensive activities of Arotinolol.Investigational
BucindololArotinolol may increase the orthostatic hypotensive activities of Bucindolol.Investigational
BufexamacBufexamac may decrease the antihypertensive activities of Arotinolol.Approved, Experimental
BumadizoneBumadizone may decrease the antihypertensive activities of Arotinolol.Experimental
BumetanideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Bumetanide.Approved
BunazosinArotinolol may increase the orthostatic hypotensive activities of Bunazosin.Investigational
BupivacaineThe serum concentration of Bupivacaine can be increased when it is combined with Arotinolol.Approved, Investigational
BupropionThe metabolism of Arotinolol can be decreased when combined with Bupropion.Approved
CabergolineArotinolol may increase the vasoconstricting activities of Cabergoline.Approved
CaffeineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Caffeine.Approved
CanagliflozinThe risk or severity of adverse effects can be increased when Arotinolol is combined with Canagliflozin.Approved
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Candesartan cilexetil.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Captopril.Approved
CarbamoylcholineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Carbachol.Approved
Carbaspirin calciumCarbaspirin calcium may decrease the antihypertensive activities of Arotinolol.Experimental, Investigational
CarbetocinThe risk or severity of adverse effects can be increased when Arotinolol is combined with Carbetocin.Approved, Investigational
CarboxyamidotriazoleThe risk or severity of hypotension can be increased when Arotinolol is combined with Carboxyamidotriazole.Investigational
CarbutamideArotinolol may increase the hypoglycemic activities of Carbutamide.Experimental
CaroverineThe risk or severity of hypotension can be increased when Arotinolol is combined with Caroverine.Experimental
CarprofenCarprofen may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved, Withdrawn
CarteololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Carteolol.Approved
CarvedilolArotinolol may increase the orthostatic hypotensive activities of Carvedilol.Approved, Investigational
CastanospermineCastanospermine may decrease the antihypertensive activities of Arotinolol.Experimental
CelecoxibCelecoxib may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
CevimelineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Cevimeline.Approved
ChloroquineThe metabolism of Arotinolol can be decreased when combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorothiazideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Chlorothiazide.Approved, Vet Approved
ChlorproethazineChlorproethazine may increase the hypotensive activities of Arotinolol.Experimental
ChlorpromazineArotinolol may increase the orthostatic hypotensive activities of Chlorpromazine.Approved, Investigational, Vet Approved
ChlorpropamideArotinolol may increase the hypoglycemic activities of Chlorpropamide.Approved, Investigational
ChlorthalidoneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Chlorthalidone.Approved
Choline magnesium trisalicylateCholine magnesium trisalicylate may decrease the antihypertensive activities of Arotinolol.Approved
CilazaprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Cilazapril.Approved
CilnidipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Cilnidipine.Approved, Investigational
CimetidineThe metabolism of Arotinolol can be decreased when combined with Cimetidine.Approved, Investigational
CinnarizineThe risk or severity of hypotension can be increased when Arotinolol is combined with Cinnarizine.Approved, Investigational
ClemastineThe metabolism of Arotinolol can be decreased when combined with Clemastine.Approved, Investigational
ClevidipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Clevidipine.Approved, Investigational
ClofarabineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Clofarabine.Approved, Investigational
ClomipramineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Clomipramine.Approved, Investigational, Vet Approved
ClonidineClonidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
ClonixinClonixin may decrease the antihypertensive activities of Arotinolol.Approved
ClozapineArotinolol may increase the orthostatic hypotensive activities of Clozapine.Approved
ConivaptanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Conivaptan.Approved, Investigational
CoumaphosCoumaphos may increase the bradycardic activities of Arotinolol.Vet Approved
CurcuminCurcumin may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
CyclandelateThe risk or severity of hypotension can be increased when Arotinolol is combined with Cyclandelate.Approved
CyclosporineThe risk or severity of hyperkalemia can be increased when Arotinolol is combined with Cyclosporine.Approved, Investigational, Vet Approved
CymarinArotinolol may increase the bradycardic activities of Cymarin.Experimental
DapagliflozinThe risk or severity of adverse effects can be increased when Arotinolol is combined with Dapagliflozin.Approved
DapiprazoleArotinolol may increase the orthostatic hypotensive activities of Dapiprazole.Approved
DapoxetineThe serum concentration of Arotinolol can be increased when it is combined with Dapoxetine.Investigational
DarodipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Darodipine.Experimental
DecamethoniumDecamethonium may increase the bradycardic activities of Arotinolol.Approved
DemecariumDemecarium may increase the bradycardic activities of Arotinolol.Approved
DesfluraneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Desflurane.Approved
DeslanosideArotinolol may increase the bradycardic activities of Deslanoside.Approved
DesvenlafaxineThe serum concentration of Arotinolol can be increased when it is combined with Desvenlafaxine.Approved, Investigational
DetomidineDetomidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Vet Approved
DexmedetomidineDexmedetomidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Vet Approved
DexniguldipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Dexniguldipine.Experimental
DextroamphetamineArotinolol may increase the orthostatic hypotensive activities of Dextroamphetamine.Approved, Illicit
DexverapamilThe risk or severity of hypotension can be increased when Arotinolol is combined with Dexverapamil.Experimental
DichlorvosDichlorvos may increase the bradycardic activities of Arotinolol.Vet Approved
DiclofenacDiclofenac may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
DiclofenamideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Diclofenamide.Approved, Investigational
DifenpiramideDifenpiramide may decrease the antihypertensive activities of Arotinolol.Experimental
DiflunisalDiflunisal may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
DigitoxinArotinolol may increase the bradycardic activities of Digitoxin.Approved, Investigational
DigoxinArotinolol may increase the bradycardic activities of Digoxin.Approved
Digoxin Immune Fab (Ovine)Arotinolol may increase the bradycardic activities of Digoxin Immune Fab (Ovine).Approved
DihydroergotamineDihydroergotamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
DiltiazemThe risk or severity of hypotension can be increased when Arotinolol is combined with Diltiazem.Approved, Investigational
DinutuximabThe risk or severity of adverse effects can be increased when Arotinolol is combined with Dinutuximab.Approved, Investigational
DiphenhydramineThe metabolism of Arotinolol can be decreased when combined with Diphenhydramine.Approved, Investigational
DipivefrinDipivefrin may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
DipyridamoleDipyridamole may increase the bradycardic activities of Arotinolol.Approved
DisopyramideDisopyramide may increase the bradycardic activities of Arotinolol.Approved
DistigmineDistigmine may increase the bradycardic activities of Arotinolol.Experimental
DL-MethylephedrineDL-Methylephedrine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
DonepezilDonepezil may increase the bradycardic activities of Arotinolol.Approved
DotarizineThe risk or severity of hypotension can be increased when Arotinolol is combined with Dotarizine.Investigational
DoxazosinArotinolol may increase the orthostatic hypotensive activities of Doxazosin.Approved
DoxepinArotinolol may increase the orthostatic hypotensive activities of Doxepin.Approved, Investigational
DronedaroneDronedarone may increase the bradycardic activities of Arotinolol.Approved
DroperidolArotinolol may increase the orthostatic hypotensive activities of Droperidol.Approved, Vet Approved
DroxicamDroxicam may decrease the antihypertensive activities of Arotinolol.Withdrawn
DroxidopaDroxidopa may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
DuloxetineArotinolol may increase the orthostatic hypotensive activities of Duloxetine.Approved
DuvelisibDuvelisib may decrease the antihypertensive activities of Arotinolol.Investigational
E-6201E-6201 may decrease the antihypertensive activities of Arotinolol.Investigational
EchothiophateEchothiophate may increase the bradycardic activities of Arotinolol.Approved
EdrophoniumEdrophonium may increase the bradycardic activities of Arotinolol.Approved
EfonidipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Efonidipine.Approved, Investigational
EmopamilThe risk or severity of hypotension can be increased when Arotinolol is combined with Emopamil.Experimental
EmpagliflozinThe risk or severity of adverse effects can be increased when Arotinolol is combined with Empagliflozin.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Arotinolol is combined with Enalaprilat.Approved
EperisoneThe risk or severity of hypotension can be increased when Arotinolol is combined with Eperisone.Approved, Investigational
EphedraEphedra may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Nutraceutical, Withdrawn
EpibatidineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Epibatidine.Experimental
EpinephrineEpinephrine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Vet Approved
EpirizoleEpirizole may decrease the antihypertensive activities of Arotinolol.Approved
EplerenoneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Eplerenone.Approved
EpoprostenolThe risk or severity of adverse effects can be increased when Arotinolol is combined with Epoprostenol.Approved
EprosartanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Eprosartan.Approved
Ergoloid mesylateArotinolol may increase the vasoconstricting activities of Ergoloid mesylate.Approved
ErgonovineArotinolol may increase the vasoconstricting activities of Ergonovine.Approved
ErgotamineErgotamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
EscitalopramArotinolol may increase the orthostatic hypotensive activities of Escitalopram.Approved, Investigational
EsmololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Esmolol.Approved
Etacrynic acidThe risk or severity of adverse effects can be increased when Arotinolol is combined with Etacrynic acid.Approved, Investigational
EtanerceptEtanercept may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
EthenzamideEthenzamide may decrease the antihypertensive activities of Arotinolol.Experimental
EthosuximideThe risk or severity of hypotension can be increased when Arotinolol is combined with Ethosuximide.Approved
EtodolacEtodolac may decrease the antihypertensive activities of Arotinolol.Approved, Investigational, Vet Approved
EtofenamateEtofenamate may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
EtomidateThe therapeutic efficacy of Etomidate can be decreased when used in combination with Arotinolol.Approved
EtoperidoneThe serum concentration of Arotinolol can be increased when it is combined with Etoperidone.Withdrawn
EtoricoxibEtoricoxib may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
Evening primrose oilEvening primrose oil may decrease the antihypertensive activities of Arotinolol.Investigational, Nutraceutical
ExisulindExisulind may decrease the antihypertensive activities of Arotinolol.Investigational
FelbinacFelbinac may decrease the antihypertensive activities of Arotinolol.Experimental
FelodipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Felodipine.Approved, Investigational
FenbufenFenbufen may decrease the antihypertensive activities of Arotinolol.Approved
FendilineThe risk or severity of hypotension can be increased when Arotinolol is combined with Fendiline.Withdrawn
FenoldopamThe risk or severity of adverse effects can be increased when Arotinolol is combined with Fenoldopam.Approved
FenoprofenFenoprofen may decrease the antihypertensive activities of Arotinolol.Approved
FentanylFentanyl may increase the bradycardic activities of Arotinolol.Approved, Illicit, Investigational, Vet Approved
FenthionFenthion may increase the bradycardic activities of Arotinolol.Vet Approved
FentiazacFentiazac may decrease the antihypertensive activities of Arotinolol.Experimental
FeprazoneFeprazone may decrease the antihypertensive activities of Arotinolol.Experimental
Ferulic acidFerulic acid may decrease the antihypertensive activities of Arotinolol.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Fimasartan.Approved, Investigational
FingolimodArotinolol may increase the bradycardic activities of Fingolimod.Approved, Investigational
Fish oilThe risk or severity of hypotension can be increased when Arotinolol is combined with Fish oil.Approved, Nutraceutical
FloctafenineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Floctafenine.Approved, Withdrawn
FlunarizineThe risk or severity of hypotension can be increased when Arotinolol is combined with Flunarizine.Approved
FlunixinFlunixin may decrease the antihypertensive activities of Arotinolol.Vet Approved
FlunoxaprofenFlunoxaprofen may decrease the antihypertensive activities of Arotinolol.Experimental
FluoxetineThe serum concentration of Arotinolol can be increased when it is combined with Fluoxetine.Approved, Vet Approved
FlupentixolArotinolol may increase the orthostatic hypotensive activities of Flupentixol.Approved, Investigational, Withdrawn
FluphenazineFluphenazine may increase the hypotensive activities of Arotinolol.Approved
FlurbiprofenFlurbiprofen may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
FluspirileneThe risk or severity of hypotension can be increased when Arotinolol is combined with Fluspirilene.Approved, Investigational
FluvoxamineThe metabolism of Arotinolol can be decreased when combined with Fluvoxamine.Approved, Investigational
FosinoprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Fosinopril.Approved
FurosemideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Furosemide.Approved, Vet Approved
GabapentinThe risk or severity of hypotension can be increased when Arotinolol is combined with Gabapentin.Approved, Investigational
GalantamineGalantamine may increase the bradycardic activities of Arotinolol.Approved
Gallamine TriethiodideGallamine Triethiodide may increase the bradycardic activities of Arotinolol.Approved
GallopamilThe risk or severity of hypotension can be increased when Arotinolol is combined with Gallopamil.Investigational
Ginkgo bilobaGinkgo biloba may increase the bradycardic activities of Arotinolol.Approved, Investigational, Nutraceutical
GitoformateArotinolol may increase the bradycardic activities of Gitoformate.Experimental
GlibornurideArotinolol may increase the hypoglycemic activities of Glibornuride.Investigational, Withdrawn
GliclazideArotinolol may increase the hypoglycemic activities of Gliclazide.Approved
GlimepirideArotinolol may increase the hypoglycemic activities of Glimepiride.Approved
GlipizideArotinolol may increase the hypoglycemic activities of Glipizide.Approved, Investigational
GliquidoneArotinolol may increase the hypoglycemic activities of Gliquidone.Approved, Investigational
GlisoxepideArotinolol may increase the hypoglycemic activities of Glisoxepide.Investigational
GlyburideArotinolol may increase the hypoglycemic activities of Glyburide.Approved
GTS-21The risk or severity of adverse effects can be increased when Arotinolol is combined with GTS-21.Investigational
GuacetisalGuacetisal may decrease the antihypertensive activities of Arotinolol.Experimental
GuanabenzGuanabenz may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
GuanfacineThe therapeutic efficacy of Guanfacine can be decreased when used in combination with Arotinolol.Approved, Investigational
HalothaneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Halothane.Approved, Vet Approved
HexobarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Hexobarbital.Approved
HigenamineHigenamine may decrease the antihypertensive activities of Arotinolol.Investigational
Huperzine AHuperzine A may increase the bradycardic activities of Arotinolol.Approved, Investigational
HydralazineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Hydralazine.Approved
HydrochlorothiazideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Hydroflumethiazide.Approved, Investigational
HydroxychloroquineThe metabolism of Arotinolol can be decreased when combined with Hydroxychloroquine.Approved
IbuprofenIbuprofen may decrease the antihypertensive activities of Arotinolol.Approved
IbuproxamIbuproxam may decrease the antihypertensive activities of Arotinolol.Withdrawn
IcatibantIcatibant may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
IloperidoneArotinolol may increase the orthostatic hypotensive activities of Iloperidone.Approved
IloprostThe risk or severity of adverse effects can be increased when Arotinolol is combined with Iloprost.Approved, Investigational
ImidaprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Imidapril.Investigational
Imidazole salicylateImidazole salicylate may decrease the antihypertensive activities of Arotinolol.Experimental
ImipramineArotinolol may increase the orthostatic hypotensive activities of Imipramine.Approved
IndalpineThe serum concentration of Arotinolol can be increased when it is combined with Indalpine.Investigational, Withdrawn
IndapamideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Indapamide.Approved
IndobufenIndobufen may decrease the antihypertensive activities of Arotinolol.Investigational
IndomethacinIndomethacin may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
IndoprofenIndoprofen may decrease the antihypertensive activities of Arotinolol.Withdrawn
IndoraminArotinolol may increase the orthostatic hypotensive activities of Indoramin.Withdrawn
Insulin HumanArotinolol may increase the hypoglycemic activities of Insulin Human.Approved, Investigational
Insulin PorkArotinolol may increase the hypoglycemic activities of Insulin Pork.Approved
IpidacrineIpidacrine may increase the bradycardic activities of Arotinolol.Experimental
IrbesartanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Irbesartan.Approved, Investigational
IsocarboxazidThe risk or severity of adverse effects can be increased when Arotinolol is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Isoflurane.Approved, Vet Approved
IsoflurophateIsoflurophate may increase the bradycardic activities of Arotinolol.Approved, Investigational, Withdrawn
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Arotinolol is combined with Isosorbide Dinitrate.Approved, Investigational
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Arotinolol is combined with Isosorbide Mononitrate.Approved
IsoxicamIsoxicam may decrease the antihypertensive activities of Arotinolol.Withdrawn
IsoxsuprineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Isoxsuprine.Approved, Withdrawn
IsradipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Isradipine.Approved, Investigational
KebuzoneKebuzone may decrease the antihypertensive activities of Arotinolol.Experimental
KetoprofenKetoprofen may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
KetorolacKetorolac may decrease the antihypertensive activities of Arotinolol.Approved
LabetalolArotinolol may increase the orthostatic hypotensive activities of Labetalol.Approved
LacidipineArotinolol may increase the hypotensive activities of Lacidipine.Approved, Investigational
LamotrigineThe risk or severity of hypotension can be increased when Arotinolol is combined with Lamotrigine.Approved, Investigational
Lanatoside CArotinolol may increase the bradycardic activities of Lanatoside C.Experimental
LeflunomideLeflunomide may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
LercanidipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Lercanidipine.Approved, Investigational
LevetiracetamThe risk or severity of hypotension can be increased when Arotinolol is combined with Levetiracetam.Approved, Investigational
LevobunololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Levobunolol.Approved
LevobupivacaineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Levobupivacaine.Approved, Investigational
LevodopaArotinolol may increase the orthostatic hypotensive activities of Levodopa.Approved
LevomilnacipranThe serum concentration of Arotinolol can be increased when it is combined with Levomilnacipran.Approved, Investigational
LevonordefrinLevonordefrin may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
LevosimendanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Levosimendan.Approved, Investigational
LidocaineThe serum concentration of Lidocaine can be increased when it is combined with Arotinolol.Approved, Vet Approved
LidoflazineThe risk or severity of hypotension can be increased when Arotinolol is combined with Lidoflazine.Experimental
LisdexamfetamineArotinolol may increase the orthostatic hypotensive activities of Lisdexamfetamine.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Lisinopril.Approved, Investigational
LisofyllineLisofylline may decrease the antihypertensive activities of Arotinolol.Investigational
LobelineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Lobeline.Investigational
LofexidineLofexidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
LomerizineThe risk or severity of hypotension can be increased when Arotinolol is combined with Lomerizine.Experimental
LonazolacLonazolac may decrease the antihypertensive activities of Arotinolol.Experimental
LoperamideThe risk or severity of hypotension can be increased when Arotinolol is combined with Loperamide.Approved
LornoxicamLornoxicam may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Losartan.Approved
LoxoprofenLoxoprofen may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
LumiracoxibLumiracoxib may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
Magnesium salicylateMagnesium salicylate may decrease the antihypertensive activities of Arotinolol.Approved
Magnesium sulfateThe risk or severity of hypotension can be increased when Arotinolol is combined with Magnesium sulfate.Approved, Investigational, Vet Approved
MalathionMalathion may increase the bradycardic activities of Arotinolol.Approved, Investigational
ManidipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Manidipine.Approved, Investigational
MannitolThe risk or severity of adverse effects can be increased when Arotinolol is combined with Mannitol.Approved, Investigational
MasoprocolMasoprocol may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
MecamylamineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Mecamylamine.Approved, Investigational
Meclofenamic acidMeclofenamic acid may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
MedetomidineMedetomidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Vet Approved
Mefenamic acidMefenamic acid may decrease the antihypertensive activities of Arotinolol.Approved
MefloquineMefloquine may increase the bradycardic activities of Arotinolol.Approved, Investigational
MeloxicamMeloxicam may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
MemantineMemantine may increase the bradycardic activities of Arotinolol.Approved, Investigational
MentholThe risk or severity of hypotension can be increased when Arotinolol is combined with Menthol.Approved
MepivacaineThe serum concentration of Mepivacaine can be increased when it is combined with Arotinolol.Approved, Vet Approved
MesalazineMesalazine may decrease the antihypertensive activities of Arotinolol.Approved
MesoridazineMesoridazine may increase the hypotensive activities of Arotinolol.Approved, Investigational
MetahexamideArotinolol may increase the hypoglycemic activities of Metahexamide.Experimental
MetamizoleMetamizole may decrease the antihypertensive activities of Arotinolol.Approved, Investigational, Withdrawn
MethacholineArotinolol may increase the bronchoconstrictory activities of Methacholine.Approved, Investigational
MethamphetamineMethamphetamine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Illicit
Methanesulfonyl FluorideMethanesulfonyl Fluoride may increase the bradycardic activities of Arotinolol.Investigational
MethazolamideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Methazolamide.Approved
MethohexitalThe serum concentration of Arotinolol can be decreased when it is combined with Methohexital.Approved
MethotrimeprazineArotinolol may increase the orthostatic hypotensive activities of Methotrimeprazine.Approved, Investigational
MethsuximideThe risk or severity of hypotension can be increased when Arotinolol is combined with Methsuximide.Approved
MethyclothiazideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Methyclothiazide.Approved
MethyldopaMethyldopa may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
Methylene blueMethylene blue may increase the hypotensive activities of Arotinolol.Approved, Investigational
MethylergometrineArotinolol may increase the vasoconstricting activities of Methylergometrine.Approved
MethylphenobarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Methylphenobarbital.Approved
MetildigoxinArotinolol may increase the bradycardic activities of Metildigoxin.Experimental
MetipranololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Metipranolol.Approved
MetoclopramideMetoclopramide may increase the bradycardic activities of Arotinolol.Approved, Investigational
MetolazoneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Metolazone.Approved
MetoprololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Metoprolol.Approved, Investigational
MibefradilThe risk or severity of hypotension can be increased when Arotinolol is combined with Mibefradil.Investigational, Withdrawn
MidodrineArotinolol may increase the bradycardic activities of Midodrine.Approved
MilnacipranThe serum concentration of Arotinolol can be increased when it is combined with Milnacipran.Approved, Investigational
MinaprineMinaprine may increase the bradycardic activities of Arotinolol.Approved
MinoxidilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Minoxidil.Approved, Investigational
MizoribineMizoribine may decrease the antihypertensive activities of Arotinolol.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Moexipril.Approved
MofebutazoneMofebutazone may decrease the antihypertensive activities of Arotinolol.Experimental
MoricizineMoricizine may increase the hypotensive activities of Arotinolol.Approved, Investigational, Withdrawn
MorphineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Morphine.Approved, Investigational
MoxonidineMoxonidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
Mycophenolate mofetilMycophenolate mofetil may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
Mycophenolic acidMycophenolic acid may decrease the antihypertensive activities of Arotinolol.Approved
NabiloneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nabilone.Approved, Investigational
NabumetoneNabumetone may decrease the antihypertensive activities of Arotinolol.Approved
NadololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nadolol.Approved
NafamostatNafamostat may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
NaftifineNaftifine may decrease the antihypertensive activities of Arotinolol.Approved
NaftopidilThe risk or severity of hypotension can be increased when Arotinolol is combined with Naftopidil.Investigational
NaphazolineThe therapeutic efficacy of Naphazoline can be decreased when used in combination with Arotinolol.Approved
NaproxenNaproxen may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
NebivololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nebivolol.Approved, Investigational
NefazodoneArotinolol may increase the orthostatic hypotensive activities of Nefazodone.Approved, Withdrawn
NeostigmineNeostigmine may increase the bradycardic activities of Arotinolol.Approved, Vet Approved
NepafenacNepafenac may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
NesiritideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nesiritide.Approved, Investigational
NicardipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Nicardipine.Approved, Investigational
NicergolineArotinolol may increase the orthostatic hypotensive activities of Nicergoline.Approved, Investigational
NicorandilNicorandil may increase the hypotensive activities of Arotinolol.Approved, Investigational
NicotineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nicotine.Approved
NifedipineThe risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Arotinolol.Approved
NifenazoneNifenazone may decrease the antihypertensive activities of Arotinolol.Experimental
Niflumic AcidNiflumic Acid may decrease the antihypertensive activities of Arotinolol.Approved
NiguldipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Niguldipine.Experimental
NiludipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Niludipine.Experimental
NilvadipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Nilvadipine.Approved, Investigational
NimesulideThe risk or severity of hypotension can be increased when Arotinolol is combined with Nimesulide.Approved, Investigational, Withdrawn
NimodipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Nimodipine.Approved, Investigational
NisoldipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Nisoldipine.Approved
NitrendipineThe risk or severity of hypotension can be increased when Arotinolol is combined with Nitrendipine.Approved, Investigational
Nitric OxideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nitric Oxide.Approved
NitroaspirinNitroaspirin may decrease the antihypertensive activities of Arotinolol.Investigational
NitroglycerinThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nitroglycerin.Approved, Investigational
NitroprussideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nitroprusside.Approved, Investigational
Nitrous acidThe risk or severity of adverse effects can be increased when Arotinolol is combined with Nitrous acid.Approved, Investigational
NorepinephrineNorepinephrine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
NortriptylineArotinolol may increase the orthostatic hypotensive activities of Nortriptyline.Approved
NylidrinThe risk or severity of hypotension can be increased when Arotinolol is combined with Nylidrin.Approved
ObinutuzumabThe risk or severity of adverse effects can be increased when Arotinolol is combined with Obinutuzumab.Approved, Investigational
OlanzapineArotinolol may increase the orthostatic hypotensive activities of Olanzapine.Approved, Investigational
OleandrinArotinolol may increase the bradycardic activities of Oleandrin.Experimental, Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Olmesartan.Approved, Investigational
OlopatadineOlopatadine may decrease the antihypertensive activities of Arotinolol.Approved
OlsalazineOlsalazine may decrease the antihypertensive activities of Arotinolol.Approved
OrgoteinOrgotein may decrease the antihypertensive activities of Arotinolol.Vet Approved
OtiloniumThe risk or severity of hypotension can be increased when Arotinolol is combined with Otilonium.Experimental, Investigational
OuabainArotinolol may increase the bradycardic activities of Ouabain.Approved
OxaprozinOxaprozin may decrease the antihypertensive activities of Arotinolol.Approved
OxprenololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Oxprenolol.Approved
OxymetazolineThe therapeutic efficacy of Oxymetazoline can be decreased when used in combination with Arotinolol.Approved, Investigational
OxyphenbutazoneOxyphenbutazone may decrease the antihypertensive activities of Arotinolol.Approved, Withdrawn
PaclitaxelThe risk or severity of adverse effects can be increased when Arotinolol is combined with Paclitaxel.Approved, Vet Approved
PaliperidonePaliperidone may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
PalmidrolPalmidrol may decrease the antihypertensive activities of Arotinolol.Experimental, Nutraceutical
PapaverineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Papaverine.Approved, Investigational
ParaoxonParaoxon may increase the bradycardic activities of Arotinolol.Experimental
ParecoxibParecoxib may decrease the antihypertensive activities of Arotinolol.Approved
ParoxetineThe serum concentration of Arotinolol can be increased when it is combined with Paroxetine.Approved, Investigational
ParthenolideParthenolide may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of hypotension can be increased when Arotinolol is combined with Penfluridol.Experimental
PentobarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Pentobarbital.Approved, Investigational, Vet Approved
PerazinePerazine may increase the hypotensive activities of Arotinolol.Approved, Investigational
PergolidePergolide may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational, Vet Approved, Withdrawn
PerindoprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Perindopril.Approved
PerphenazinePerphenazine may increase the hypotensive activities of Arotinolol.Approved
PeruvosideArotinolol may increase the bradycardic activities of Peruvoside.Experimental
PhenelzineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Phenelzine.Approved
PhenobarbitalPhenobarbital may increase the hypotensive activities of Arotinolol.Approved, Investigational
PhenoxybenzamineArotinolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.Approved
PhentolamineArotinolol may increase the orthostatic hypotensive activities of Phentolamine.Approved
PhenylbutazonePhenylbutazone may decrease the antihypertensive activities of Arotinolol.Approved, Vet Approved
PhenylephrineThe therapeutic efficacy of Phenylephrine can be decreased when used in combination with Arotinolol.Approved
PhysostigminePhysostigmine may increase the bradycardic activities of Arotinolol.Approved, Investigational
PilocarpineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Pilocarpine.Approved, Investigational
PimecrolimusPimecrolimus may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
PinaveriumThe risk or severity of hypotension can be increased when Arotinolol is combined with Pinaverium.Approved
PindololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Pipamperone.Approved, Investigational
PirfenidonePirfenidone may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
PiroxicamPiroxicam may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
PirprofenPirprofen may decrease the antihypertensive activities of Arotinolol.Experimental
PizotifenArotinolol may increase the orthostatic hypotensive activities of Pizotifen.Approved
Potassium ChlorideThe risk or severity of hyperkalemia can be increased when Potassium Chloride is combined with Arotinolol.Approved, Withdrawn
PramipexoleThe risk or severity of adverse effects can be increased when Arotinolol is combined with Pramipexole.Approved, Investigational
PranoprofenPranoprofen may decrease the antihypertensive activities of Arotinolol.Experimental, Investigational
PrazosinArotinolol may increase the orthostatic hypotensive activities of Prazosin.Approved
PrenylamineThe risk or severity of hypotension can be increased when Arotinolol is combined with Prenylamine.Withdrawn
PrimaquineThe metabolism of Arotinolol can be decreased when combined with Primaquine.Approved
PrimidoneThe serum concentration of Arotinolol can be decreased when it is combined with Primidone.Approved, Vet Approved
ProchlorperazineThe serum concentration of Arotinolol can be increased when it is combined with Prochlorperazine.Approved, Vet Approved
ProglumetacinProglumetacin may decrease the antihypertensive activities of Arotinolol.Experimental
PromazineArotinolol may increase the orthostatic hypotensive activities of Promazine.Approved, Vet Approved
PromethazineThe serum concentration of Arotinolol can be increased when it is combined with Promethazine.Approved, Investigational
PropacetamolPropacetamol may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
PropafenoneThe risk or severity of adverse effects can be increased when Propafenone is combined with Arotinolol.Approved
PropericiazineArotinolol may increase the orthostatic hypotensive activities of Propericiazine.Approved, Investigational
PropiomazineArotinolol may increase the orthostatic hypotensive activities of Propiomazine.Approved
PropiopromazinePropiopromazine may increase the hypotensive activities of Arotinolol.Vet Approved
PropiverineArotinolol may increase the orthostatic hypotensive activities of Propiverine.Approved, Investigational
PropofolThe risk or severity of adverse effects can be increased when Arotinolol is combined with Propofol.Approved, Investigational, Vet Approved
PropranololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Propranolol.Approved, Investigational
PropyphenazonePropyphenazone may decrease the antihypertensive activities of Arotinolol.Experimental
ProquazoneProquazone may decrease the antihypertensive activities of Arotinolol.Experimental
ProscillaridinArotinolol may increase the bradycardic activities of Proscillaridin.Experimental
PseudoephedrineThe therapeutic efficacy of Pseudoephedrine can be decreased when used in combination with Arotinolol.Approved
PTC299PTC299 may decrease the antihypertensive activities of Arotinolol.Investigational
PyridostigminePyridostigmine may increase the bradycardic activities of Arotinolol.Approved, Investigational
QuetiapineArotinolol may increase the orthostatic hypotensive activities of Quetiapine.Approved
QuinaprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Quinapril.Approved, Investigational
QuinidineArotinolol may increase the orthostatic hypotensive activities of Quinidine.Approved, Investigational
RacepinephrineRacepinephrine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved
RamiprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Ramipril.Approved
RasagilineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Rasagiline.Approved
RegorafenibRegorafenib may increase the bradycardic activities of Arotinolol.Approved
RemifentanilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Remifentanil.Approved
ReserpineReserpine may increase the hypotensive activities of Arotinolol.Approved, Investigational
ResveratrolResveratrol may decrease the antihypertensive activities of Arotinolol.Approved, Experimental, Investigational
RifapentineThe serum concentration of Arotinolol can be decreased when it is combined with Rifapentine.Approved, Investigational
RifaximinThe serum concentration of Arotinolol can be decreased when it is combined with Rifaximin.Approved, Investigational
RiociguatThe risk or severity of adverse effects can be increased when Arotinolol is combined with Riociguat.Approved
RisperidoneArotinolol may increase the hypotensive activities of Risperidone.Approved, Investigational
RivastigmineArotinolol may increase the bradycardic activities of Rivastigmine.Approved, Investigational
RofecoxibRofecoxib may decrease the antihypertensive activities of Arotinolol.Approved, Investigational, Withdrawn
RomifidineRomifidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Vet Approved
RopiniroleThe therapeutic efficacy of Ropinirole can be decreased when used in combination with Arotinolol.Approved, Investigational
RopivacaineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Ropivacaine.Approved
RotigotineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Rotigotine.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Sacubitril.Approved
SalbutamolThe therapeutic efficacy of Salbutamol can be decreased when used in combination with Arotinolol.Approved, Vet Approved
SalicylamideSalicylamide may decrease the antihypertensive activities of Arotinolol.Approved
Salicylic acidSalicylic acid may decrease the antihypertensive activities of Arotinolol.Approved, Investigational, Vet Approved
SalmeterolThe therapeutic efficacy of Salmeterol can be decreased when used in combination with Arotinolol.Approved
SalsalateSalsalate may decrease the antihypertensive activities of Arotinolol.Approved
SecobarbitalThe serum concentration of Arotinolol can be decreased when it is combined with Secobarbital.Approved, Vet Approved
SelegilineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Selegiline.Approved, Investigational, Vet Approved
SeletracetamThe risk or severity of hypotension can be increased when Arotinolol is combined with Seletracetam.Investigational
SemapimodSemapimod may decrease the antihypertensive activities of Arotinolol.Investigational
SeratrodastSeratrodast may decrease the antihypertensive activities of Arotinolol.Approved
SerrapeptaseSerrapeptase may decrease the antihypertensive activities of Arotinolol.Investigational
SertralineThe serum concentration of Arotinolol can be increased when it is combined with Sertraline.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Sevoflurane.Approved, Vet Approved
SilodosinArotinolol may increase the orthostatic hypotensive activities of Silodosin.Approved
SotalolThe risk or severity of adverse effects can be increased when Arotinolol is combined with Sotalol.Approved
SpironolactoneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Spironolactone.Approved
SRT501SRT501 may decrease the antihypertensive activities of Arotinolol.Investigational
StreptokinaseThe risk or severity of adverse effects can be increased when Arotinolol is combined with Streptokinase.Approved, Investigational
SufentanilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Sufentanil.Approved, Investigational
SulfasalazineSulfasalazine may decrease the antihypertensive activities of Arotinolol.Approved
SulindacSulindac may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
SuprofenSuprofen may decrease the antihypertensive activities of Arotinolol.Approved, Withdrawn
SuxibuzoneSuxibuzone may decrease the antihypertensive activities of Arotinolol.Experimental
TacrineTacrine may increase the bradycardic activities of Arotinolol.Investigational, Withdrawn
TafenoquineThe metabolism of Arotinolol can be decreased when combined with Tafenoquine.Approved, Investigational
TamsulosinArotinolol may increase the orthostatic hypotensive activities of Tamsulosin.Approved, Investigational
TarenflurbilTarenflurbil may decrease the antihypertensive activities of Arotinolol.Investigational
TelmisartanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Telmisartan.Approved, Investigational
TenidapTenidap may decrease the antihypertensive activities of Arotinolol.Experimental
TenoxicamTenoxicam may decrease the antihypertensive activities of Arotinolol.Approved
TepoxalinTepoxalin may decrease the antihypertensive activities of Arotinolol.Vet Approved
TerazosinArotinolol may increase the orthostatic hypotensive activities of Terazosin.Approved
TerbinafineThe metabolism of Arotinolol can be decreased when combined with Terbinafine.Approved, Investigational, Vet Approved
TeriflunomideTeriflunomide may decrease the antihypertensive activities of Arotinolol.Approved
TerodilineThe risk or severity of hypotension can be increased when Arotinolol is combined with Terodiline.Experimental
TetrahydropalmatineThe risk or severity of hypotension can be increased when Arotinolol is combined with Tetrahydropalmatine.Investigational
TetrandrineThe risk or severity of hypotension can be increased when Arotinolol is combined with Tetrandrine.Experimental
ThalidomideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe serum concentration of Arotinolol can be decreased when it is combined with Thiamylal.Approved, Vet Approved
ThiazinamThiazinam may increase the hypotensive activities of Arotinolol.Experimental
ThiethylperazineThiethylperazine may increase the hypotensive activities of Arotinolol.Withdrawn
ThiopentalThe serum concentration of Arotinolol can be decreased when it is combined with Thiopental.Approved, Vet Approved
ThioproperazineArotinolol may increase the orthostatic hypotensive activities of Thioproperazine.Approved
ThioridazineArotinolol may increase the orthostatic hypotensive activities of Thioridazine.Approved, Withdrawn
Tiaprofenic acidTiaprofenic acid may decrease the antihypertensive activities of Arotinolol.Approved
TimololThe risk or severity of adverse effects can be increased when Arotinolol is combined with Timolol.Approved
TinoridineTinoridine may decrease the antihypertensive activities of Arotinolol.Investigational
TizanidineTizanidine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
TolazamideArotinolol may increase the hypoglycemic activities of Tolazamide.Approved, Investigational
TolazolineArotinolol may increase the orthostatic hypotensive activities of Tolazoline.Approved, Vet Approved
TolbutamideArotinolol may increase the hypoglycemic activities of Tolbutamide.Approved, Investigational
TolcaponeThe risk or severity of adverse effects can be increased when Arotinolol is combined with Tolcapone.Approved, Withdrawn
Tolfenamic AcidThe risk or severity of hypotension can be increased when Arotinolol is combined with Tolfenamic Acid.Approved, Investigational
TolmetinTolmetin may decrease the antihypertensive activities of Arotinolol.Approved
TorasemideThe risk or severity of adverse effects can be increased when Arotinolol is combined with Torasemide.Approved
TrandolaprilThe risk or severity of adverse effects can be increased when Arotinolol is combined with Trandolapril.Approved
TranilastThe risk or severity of hypotension can be increased when Arotinolol is combined with Tranilast.Approved, Investigational
TranylcypromineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Tranylcypromine.Approved, Investigational
TrazodoneArotinolol may increase the orthostatic hypotensive activities of Trazodone.Approved, Investigational
TretinoinThe risk or severity of adverse effects can be increased when Arotinolol is combined with Tretinoin.Approved, Investigational, Nutraceutical
TriamtereneThe risk or severity of adverse effects can be increased when Arotinolol is combined with Triamterene.Approved
TribenosideTribenoside may decrease the antihypertensive activities of Arotinolol.Experimental
TrichlorfonTrichlorfon may increase the bradycardic activities of Arotinolol.Vet Approved
TrifluoperazineArotinolol may increase the orthostatic hypotensive activities of Trifluoperazine.Approved, Investigational
TriflupromazineTriflupromazine may increase the hypotensive activities of Arotinolol.Approved, Vet Approved
TrimazosinArotinolol may increase the orthostatic hypotensive activities of Trimazosin.Experimental
TrimebutineThe risk or severity of hypotension can be increased when Arotinolol is combined with Trimebutine.Approved
TrimethadioneThe risk or severity of hypotension can be increased when Arotinolol is combined with Trimethadione.Approved
TrimipramineArotinolol may increase the orthostatic hypotensive activities of Trimipramine.Approved
TriptolideTriptolide may decrease the antihypertensive activities of Arotinolol.Investigational
Trolamine salicylateTrolamine salicylate may decrease the antihypertensive activities of Arotinolol.Approved
TubocurarineTubocurarine may increase the bradycardic activities of Arotinolol.Approved
TyrothricinTyrothricin may increase the bradycardic activities of Arotinolol.Approved
UrapidilArotinolol may increase the orthostatic hypotensive activities of Urapidil.Investigational
ValaciclovirThe risk or severity of adverse effects can be increased when Arotinolol is combined with Valaciclovir.Approved, Investigational
ValdecoxibValdecoxib may decrease the antihypertensive activities of Arotinolol.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Arotinolol is combined with Valsartan.Approved, Investigational
VareniclineThe risk or severity of adverse effects can be increased when Arotinolol is combined with Varenicline.Approved, Investigational
VenlafaxineThe serum concentration of Arotinolol can be increased when it is combined with Venlafaxine.Approved
VerapamilThe risk or severity of hypotension can be increased when Arotinolol is combined with Verapamil.Approved
VinpocetineThe risk or severity of hypotension can be increased when Arotinolol is combined with Vinpocetine.Investigational
WIN 55212-2The risk or severity of hypotension can be increased when Arotinolol is combined with WIN 55212-2.Experimental
XylazineXylazine may increase the atrioventricular blocking (AV block) activities of Arotinolol.Vet Approved
XylometazolineXylometazoline may increase the atrioventricular blocking (AV block) activities of Arotinolol.Approved, Investigational
ZaltoprofenZaltoprofen may decrease the antihypertensive activities of Arotinolol.Approved, Investigational
ZiconotideThe risk or severity of hypotension can be increased when Arotinolol is combined with Ziconotide.Approved
ZileutonZileuton may decrease the antihypertensive activities of Arotinolol.Approved, Investigational, Withdrawn
ZimelidineThe serum concentration of Arotinolol can be increased when it is combined with Zimelidine.Withdrawn
ZiprasidoneArotinolol may increase the orthostatic hypotensive activities of Ziprasidone.Approved
ZomepiracZomepirac may decrease the antihypertensive activities of Arotinolol.Withdrawn
ZonisamideThe risk or severity of hypotension can be increased when Arotinolol is combined with Zonisamide.Approved, Investigational
ZuclopenthixolArotinolol may increase the orthostatic hypotensive activities of Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

General References
  1. Zhao J, Golozoubova V, Cannon B, Nedergaard J: Arotinolol is a weak partial agonist on beta 3-adrenergic receptors in brown adipocytes. Can J Physiol Pharmacol. 2001 Jul;79(7):585-93. [PubMed:11478592]
  2. Lee KS, Kim JS, Kim JW, Lee WY, Jeon BS, Kim D: A multicenter randomized crossover multiple-dose comparison study of arotinolol and propranolol in essential tremor. Parkinsonism Relat Disord. 2003 Aug;9(6):341-7. [PubMed:12853233]
  3. Wu H, Zhang Y, Huang J, Zhang Y, Liu G, Sun N, Yu Z, Zhou Y: Clinical trial of arotinolol in the treatment of hypertension: dippers vs. non-dippers. Hypertens Res. 2001 Sep;24(5):605-10. [PubMed:11675958]
  4. Miyauchi E, Matsumoto M, Kimura Y, Hattori H, Tsukio Y, Tsuchiya H, Takasaki M, Munehira J, Yamada K, Iwai K, Kawanishi K, Hoshino T, Murai H: [Clinical effect of arotinolol hydrochloride and its influence on renal function in elderly patients with essential hypertension]. Nihon Ronen Igakkai Zasshi. 1999 Aug;36(8):542-6. [PubMed:10554561]
  5. Nakashima M, Uematsu T, Takiguchi Y, Hashimoto H, Watanabe I, Morioka S, Hibino T: Effect of ophthalmic administration of S-596 (Arotinolol) on intraocular pressure and haemodynamics in health volunteers: comparison with timolol. Eur J Clin Pharmacol. 1985;28(4):391-6. [PubMed:2411566]
  6. Ganten D. and Mulrow P.J. (1990). Pharmacology of anti-hypertensive therapeutics (1st ed.). Springer .
  7. Allen R. (1988). Annual reports in medicinal chemistry (23rd ed.). Academic press.
  8. Kato R., Estabrook W. and Cayen M. (1988). Xenobiotic metabolism and disposition (2nd ed.). Taylor and Francis.
  9. Pillay V.V. (2013). Modern medical toxicology (4th ed.). Jaypee Brothers.
  10. Clinical trials [Link]
External Links
KEGG Drug
D07465
PubChem Compound
2239
PubChem Substance
310265112
ChemSpider
2152
BindingDB
81885
ChEBI
135569
ChEMBL
CHEMBL93298
Wikipedia
Arotinolol
MSDS
Download (231 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4Active Not RecruitingTreatmentChronic Kidney Disease (CKD)1
4RecruitingTreatmentHypertension,Essential1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)149-153ºC'MSDS'
boiling point (°C)599ºC at 760 mmHg'MSDS'
water solubilitySlightly solubleOfficial Monographs for Pharmacology part I.
logP2.3'MSDS'
Predicted Properties
PropertyValueSource
Water Solubility0.0225 mg/mLALOGPS
logP2.38ALOGPS
logP2.54ChemAxon
logS-4.2ALOGPS
pKa (Strongest Acidic)13.51ChemAxon
pKa (Strongest Basic)9.84ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area88.24 Å2ChemAxon
Rotatable Bond Count8ChemAxon
Refractivity96.71 m3·mol-1ChemAxon
Polarizability40.66 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Taxonomy

Description
This compound belongs to the class of organic compounds known as thiophene carboxamides. These are compounds containing a thiophene ring which bears a carboxamide.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Thiophenes
Sub Class
Thiophene carboxylic acids and derivatives
Direct Parent
Thiophene carboxamides
Alternative Parents
2-heteroaryl carboxamides / Alkylarylthioethers / 2,5-disubstituted thiophenes / 2,4-disubstituted thiazoles / Heteroaromatic compounds / Secondary alcohols / Primary carboxylic acid amides / Amino acids and derivatives / 1,2-aminoalcohols / Sulfenyl compounds
show 5 more
Substituents
2-heteroaryl carboxamide / Aryl thioether / Thiophene carboxamide / 2,4-disubstituted 1,3-thiazole / Alkylarylthioether / 2,5-disubstituted thiophene / Azole / Heteroaromatic compound / Thiazole / 1,2-aminoalcohol
show 21 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
Not Available

Targets

Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Receptor signaling protein activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. This receptor binds epinephrine and norepinephrine with approximately e...
Gene Name
ADRB1
Uniprot ID
P08588
Uniprot Name
Beta-1 adrenergic receptor
Molecular Weight
51322.1 Da
References
  1. Ganten D. and Mulrow P.J. (1990). Pharmacology of anti-hypertensive therapeutics (1st ed.). Springer .
Kind
Protein
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Ganten D. and Mulrow P.J. (1990). Pharmacology of anti-hypertensive therapeutics (1st ed.). Springer .
Kind
Protein group
Organism
Human
Pharmacological action
Yes
Actions
Antagonist
General Function
Protein heterodimerization activity
Specific Function
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) prot...

Components:
References
  1. Ganten D. and Mulrow P.J. (1990). Pharmacology of anti-hypertensive therapeutics (1st ed.). Springer .

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Steroid hydroxylase activity
Specific Function
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic...
Gene Name
CYP2D6
Uniprot ID
P10635
Uniprot Name
Cytochrome P450 2D6
Molecular Weight
55768.94 Da
References
  1. Iwaki M, Niwa T, Bandoh S, Itoh M, Hirose H, Kawase A, Komura H: Application of substrate depletion assay to evaluation of CYP isoforms responsible for stereoselective metabolism of carvedilol. Drug Metab Pharmacokinet. 2016 Dec;31(6):425-432. doi: 10.1016/j.dmpk.2016.08.007. Epub 2016 Sep 2. [PubMed:27836712]
  2. Brodde OE, Kroemer HK: Drug-drug interactions of beta-adrenoceptor blockers. Arzneimittelforschung. 2003;53(12):814-22. [PubMed:14732961]
  3. Sternieri E, Coccia CP, Pinetti D, Guerzoni S, Ferrari A: Pharmacokinetics and interactions of headache medications, part II: prophylactic treatments. Expert Opin Drug Metab Toxicol. 2006 Dec;2(6):981-1007. doi: 10.1517/17425255.2.6.981 . [PubMed:17125412]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Toxic substance binding
Specific Function
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloid...
Gene Name
ALB
Uniprot ID
P02768
Uniprot Name
Serum albumin
Molecular Weight
69365.94 Da
References
  1. Kato R., Estabrook W. and Cayen M. (1988). Xenobiotic metabolism and disposition (2nd ed.). Taylor and Francis.
Kind
Protein
Organism
Human
Pharmacological action
No
Actions
Substrate
General Function
Not Available
Specific Function
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in...
Gene Name
ORM1
Uniprot ID
P02763
Uniprot Name
Alpha-1-acid glycoprotein 1
Molecular Weight
23511.38 Da
References
  1. Kato R., Estabrook W. and Cayen M. (1988). Xenobiotic metabolism and disposition (2nd ed.). Taylor and Francis.

Drug created on October 19, 2015 13:52 / Updated on August 02, 2018 06:15